A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

BACKGROUND: Novel therapies for patients with acute myeloid leukemia (AML) are imperative, particularly for those with high-risk features. Selinexor, an exportin 1 (XPO1/CRM1) inhibitor, has demonstrated anti-leukemia activity as a single agent, as well as in combination with anthracyclines and/or D...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Amy Y., Weiner, Howard, Green, Margaret, Chang, Hua, Fulton, Noreen, Larson, Richard A., Odenike, Olatoyosi, Artz, Andrew S., Bishop, Michael R., Godley, Lucy A., Thirman, Michael J., Kosuri, Satyajit, Churpek, Jane E., Curran, Emily, Pettit, Kristen, Stock, Wendy, Liu, Hongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756334/
https://www.ncbi.nlm.nih.gov/pubmed/29304833
http://dx.doi.org/10.1186/s13045-017-0550-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5756334/
https://www.ncbi.nlm.nih.gov/pubmed/29304833
http://dx.doi.org/10.1186/s13045-017-0550-8

Ejemplares similares